Mirodenafil - CAS# 862189-95-5 Catalog No.:M10328-10 Smiles: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1C=CC(=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O

Smiles: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1C=CC(=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O

Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion

The subcutaneous tumor growth of both T24 and HeLa cell xenografts treated with PAI-039 is markedly reduced compared with untreated controls

It is generic and sold under many brand names worldwide

Agonists to the A3AR are known to induce specific anti-inflammatory effects upon chronic treatment

Mirodenafil - CAS# 862189-95-5 Catalog No.:M10328-10 Smiles: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1C=CC(=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=OMirodenafil, also known as SK3530, belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first line treatment for erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving film (50 mg). Several clinical trials were conducted, but mirodenafil has not